‘Sex in a Spray’ Draws Concerns About an ‘Age of McNookie’
PT-141, a nasal spray that is perhaps the world's first legitimate aphrodisiac, may hit the market in under three years. The Observer wonders whether such a "sure thing" will trivialize the emotional aspect of relationships.PT-141, a nasal spray that is perhaps the world’s first legitimate aphrodisiac, may hit the market in under three years. The Observer wonders whether such a “sure thing” will trivialize the emotional aspect of relationships.
WAIT, BEFORE YOU GO…Observer:
Horn of rhinoceros. Penis of tiger. Root of sea holly. Husk of the emerald-green blister beetle known as the Spanish fly. So colourful and exotic is the list of substances that have been claimed to heighten sexual appetite that it is hard not to feel a twinge of disappointment on first beholding the latest entry – a small, white plastic nasal inhaler containing an odourless, colourless synthetic chemical called PT-141. Plain as it is, however, there is one thing that distinguishes PT-141 from the 4,000 years’ worth of recorded medicinal aphrodisiacs that precede it: this one actually works.
And it could reach the market in as little as three years. The full range of possible risks and side effects has yet to be determined, but already this much is known: a dose of PT-141 results, in most cases, in a stirring in the loins in as little as 15 minutes. Women, according to one set of results, feel ‘genital warmth, tingling and throbbing’, not to mention ‘a strong desire to have sex’.
Among men who have been tested with the drug more extensively, the data set is richer: ‘With PT-141, you feel good,’ reported anonymous patient 007: ‘not only sexually aroused, you feel younger and more energetic.’ According to another patient, ‘It helped the libido. So you have the urge and the desire…’ Tales of pharmaceutically induced sexual prowess among 58-year-olds are common enough in the age of the Little Blue Pill, but they don’t typically involve quite so urgent a repertoire. Or, as patient 128 put it: ‘My wife knows. She can tell the difference between Viagra and PT-141.’
If you're reading this, you probably already know that non-profit, independent journalism is under threat worldwide. Independent news sites are overshadowed by larger heavily funded mainstream media that inundate us with hype and noise that barely scratch the surface. We believe that our readers deserve to know the full story. Truthdig writers bravely dig beneath the headlines to give you thought-provoking, investigative reporting and analysis that tells you what’s really happening and who’s rolling up their sleeves to do something about it.
Like you, we believe a well-informed public that doesn’t have blind faith in the status quo can help change the world. Your contribution of as little as $5 monthly or $35 annually will make you a groundbreaking member and lays the foundation of our work.
Book Excerpt
Seventy-five years ago in Chicago, a conservative project was hatched to cure classical economics of its aversion to patents and monopolies. The drug companies were its first and biggest beneficiaries.
Business & Economy
The pharmaceutical giant refuses to make its vaccine technology available to all.
The presidential candidate travels with a caravan of type 1 diabetes patients seeking affordable insulin in America's northern neighbor.
The president is now focusing his drive to curb drug costs on congressional efforts.
Lawmakers are trying to set aside their differences on Obamacare and reach agreement on a more immediate health care issue.
There are two leading risk factors for becoming addicted to opioids, and potentially dying of an overdose.
There are currently no responses to this article.
Be the first to respond.